Drug repurposing approaches for depression: Rationale and its clinical experience
36th World Congress on Pharmacology
July 25, 2023 | Webinar

Mimansa Kandhwal

Chitkara University, India

Posters & Accepted Abstracts: J Clin Exp Pharmacol

Abstract:

Drug discovery is a very time consuming, tedious and expensive process lasting for about two or more decades. This complexity of the process of drug discovery and sluggish pace at which new drugs are being discovered draw the attention of scientists to redefine the whole process with the help of drug repurposing. Usage of old drug moieties in any other disorder with all new mechanism is defined as repurposing. Repurposing of drugs knocks out the pre-clinical phase and related studies in order to give that molecule a redefined purpose. Data from these studies may be used in discovering newer molecules in order to save human effort, time and expenses as well. The complex etiology of depression and resistance to its treatment drives novel discoveries via therapeutic repurposing and pharmacological repositioning to treat this complex disorder. In addition to the reduction of neurotransmitters such as epinephrine and serotonin, additional processes like as inflammation, inadequate blood flow, and neurotoxicants are also being examined as possibly implicated mechanisms. Taking into consideration the aforementioned pathways has led to the development of repurposed drugs that can be used to treat treatment-resistant depression (TRD). Incorporation of AI in drug repurposing may also enhances the chances of its success rate as it deals with data digitalization which is the main core mechanism used in drug repurposing.

Biography :

Mimansa is currently pursuing her PhD from Chitkara University. She completed her high school from DAV Public School Safidon. She has her keen interest in Pharmacology and Neurological disorders. She is currently working on depression in her PhD. She has also got JRF (junior research fellowship) in DPSRU for tenure of one year.